Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997. After receiving approval by the China Securities Regulatory Commission in August 1999, the company issued 58 million A shares on the open market. In October, the company's shares were then listed on the Shanghai Stock Exchange. As of the end of 2018, the company had 960 million yuan in registered capital and total assets of 10 billion yuan. Company profile Zhejiang Medicine currently has nine major subsidiaries, including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, Zhejiang Health Creation Biotechnology Co., Ltd., Zhejiang LaiYi Medicine Co., Ltd., Zhejiang Novus Pharmaceuticals Co., Ltd., Zhejiang Changhai Pharmaceuticals Co., Ltd., Shanghai Vital Health Management Co., Ltd., NovoCodex Biopharmaceuticals. Co., Ltd., and two research units, the Pharmaceutical Industry Research Institute and the Shanghai Laiyi Biopharmaceutical R&D Center. The company has more than 6,800 employees, including more than 2,500 professional and technical personnel, who account for more than 37% of the company’s total number of employees.